EP3324990A4 - Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie - Google Patents

Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie Download PDF

Info

Publication number
EP3324990A4
EP3324990A4 EP16828163.2A EP16828163A EP3324990A4 EP 3324990 A4 EP3324990 A4 EP 3324990A4 EP 16828163 A EP16828163 A EP 16828163A EP 3324990 A4 EP3324990 A4 EP 3324990A4
Authority
EP
European Patent Office
Prior art keywords
peptides
immune
identification
mhc class
based therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16828163.2A
Other languages
German (de)
English (en)
Other versions
EP3324990A1 (fr
Inventor
Gary K. Koski
Brian J. Czerniecki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BRIAN J. CZERNIECKI
Original Assignee
Brian J Czerniecki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/041034 external-priority patent/WO2016011432A2/fr
Application filed by Brian J Czerniecki filed Critical Brian J Czerniecki
Publication of EP3324990A1 publication Critical patent/EP3324990A1/fr
Publication of EP3324990A4 publication Critical patent/EP3324990A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
EP16828163.2A 2015-07-17 2016-04-07 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie Withdrawn EP3324990A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2015/041034 WO2016011432A2 (fr) 2014-07-17 2015-07-17 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
PCT/US2016/021042 WO2017014810A1 (fr) 2015-07-17 2016-03-04 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
PCT/US2016/026542 WO2017014816A1 (fr) 2015-07-17 2016-04-07 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie

Publications (2)

Publication Number Publication Date
EP3324990A1 EP3324990A1 (fr) 2018-05-30
EP3324990A4 true EP3324990A4 (fr) 2019-04-03

Family

ID=57835029

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16828158.2A Withdrawn EP3325005A4 (fr) 2015-07-17 2016-03-04 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
EP16828163.2A Withdrawn EP3324990A4 (fr) 2015-07-17 2016-04-07 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP16828158.2A Withdrawn EP3325005A4 (fr) 2015-07-17 2016-03-04 Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie

Country Status (5)

Country Link
EP (2) EP3325005A4 (fr)
JP (3) JP2018527286A (fr)
CN (1) CN107206045A (fr)
CA (2) CA2992925A1 (fr)
WO (2) WO2017014810A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2992925A1 (fr) * 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011343A1 (fr) * 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Vaccins à base de peptides de protéine her3 et de cellules dendritiques

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183884A (en) * 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
IL145926A0 (en) * 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
EP2258712A3 (fr) * 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions et procédés permettant d'initier ou d'ameliorer les réponses des cellules T limitées par le complexe majeur d 'histocompatibilité de classe I ou II et un anticorps au moyen de motifs d'ARN non codants immunomodulateurs
US7919098B2 (en) * 2002-03-26 2011-04-05 Zensun ( Shanghai ) Sci & Tech Co., Ltd. ErbB-3 based methods and compositions for treating neoplasms
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
WO2007115571A2 (fr) * 2006-04-07 2007-10-18 Enkam Pharmaceuticals A/S Fragments peptidiques dérivés du récepteur erbb
EA017441B1 (ru) * 2006-06-15 2012-12-28 Новартис Аг Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы
JP5384672B2 (ja) * 2009-02-24 2014-01-08 エフ．ホフマン−ラ ロシュ アーゲー 癌のマーカーとしてのｓ−ＥｒｂＢ−３の使用
JP2010200693A (ja) * 2009-03-04 2010-09-16 Chiyoda Kako Kensetsu Kk 樹状細胞ワクチン製造用培養装置並びに樹状細胞の製造方法
US8765383B2 (en) * 2009-04-07 2014-07-01 Genomic Health, Inc. Methods of predicting cancer risk using gene expression in premalignant tissue
EP2461828B1 (fr) * 2009-07-31 2017-06-21 President and Fellows of Harvard College Programmation de cellules à des fins de thérapie tolérogénique
WO2011115970A1 (fr) * 2010-03-15 2011-09-22 The Trustees Of The University Of Pennsylvania Système et procédé de préparation et de conservation de cellules dendritiques matures activées
WO2012156532A1 (fr) * 2011-05-19 2012-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Anticorps anti-her3 humain et leurs utilisations
US20130251703A1 (en) * 2011-12-05 2013-09-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3
TW201601754A (zh) * 2013-09-30 2016-01-16 第一三共股份有限公司 核酸生物標記及其用途
CA2992925A1 (fr) * 2015-07-17 2017-01-26 The Trustees Of The University Of Pennsylvania Identification de peptides immunogenes de classe ii du complexe majeur d'histocompatibilite pour une immunotherapie

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011343A1 (fr) * 2014-07-17 2016-01-21 The Trustees Of The University Of Pennsylvania Vaccins à base de peptides de protéine her3 et de cellules dendritiques

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATTA JASHODEEP ET AL: "Progressive loss of anti-HER2 CD4(+) T-helper type 1 response in breast tumorigenesis and the potential for immune restoration", ONCOIMMUNOLOGY, LANDES BIOSCIENCE, US, vol. 4, no. 10, 1 April 2015 (2015-04-01), XP002782236, ISSN: 2162-402X, DOI: 10.1080/2162402X.2015.1022301 *
FRACOL MEGAN ET AL: "Loss of Anti-HER-3 CD4+ T-Helper Type 1 Immunity Occurs in Breast Tumorigenesis and is Negatively Associated with Outcomes", ANNALS OF SURGICAL ONCOLOGY, RAVEN PRESS, NEW YORK, NY, US, vol. 24, no. 2, 23 September 2016 (2016-09-23), pages 407 - 417, XP036125796, ISSN: 1068-9265, [retrieved on 20160923], DOI: 10.1245/S10434-016-5584-6 *
JASHODEEP DATTA ET AL: "Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer : Role for Immune Monitoring", JAMA ONCOLOGY, vol. 2, no. 2, 1 February 2016 (2016-02-01), US, pages 242, XP055556159, ISSN: 2374-2437, DOI: 10.1001/jamaoncol.2015.5482 *
See also references of WO2017014816A1 *

Also Published As

Publication number Publication date
CA2992925A1 (fr) 2017-01-26
EP3325005A4 (fr) 2019-03-27
JP2018527286A (ja) 2018-09-20
EP3324990A1 (fr) 2018-05-30
JP2021043204A (ja) 2021-03-18
EP3325005A1 (fr) 2018-05-30
JP2018521953A (ja) 2018-08-09
WO2017014810A1 (fr) 2017-01-26
CN107206045A (zh) 2017-09-26
WO2017014816A1 (fr) 2017-01-26
CA2992937A1 (fr) 2017-01-26

Similar Documents

Publication Publication Date Title
EP3291842A4 (fr) Vaccin à base d'une variante de survivine pour le traitement du cancer
PL3207053T3 (pl) Nowe peptydy immunogenne
ZA201806860B (en) Novel immunogenic cd1d binding peptides
EP3220953A4 (fr) Compositions et procédés d'utilisation de peptides thérapeutiques en relation avec p53 et de leurs analogues
ZA201808246B (en) Improvement of hpv l2 peptide immunogenicity
EP3523274A4 (fr) Formulations pour l'administration d'eflornithine
EP3315599A4 (fr) Vaccin antitumoral par voie orale
EP3199627A4 (fr) Peptides antigéniques tumoraux
EP3152236A4 (fr) Procédé permettant de réduire l'immunogénicité d'une protéine et d'un peptide
IL265805A (en) Arginase immunogenic peptides
HK1250662A1 (zh) 用於治療癌症的免疫原性融合蛋白
EP3178491A4 (fr) Composition destinée à améliorer l'induction de l'immunité humorale, et composition pharmaceutique vaccinale
EP3283095A4 (fr) Peptides thérapeutiques pour maladies cérébrovasculaires
EP3107450A4 (fr) Système de correspondance de base cosmétique
EP3231867A4 (fr) Peptide d'antigène tumoral
EP3223016A4 (fr) Peptides pour le ciblage de cancer gastrique, et leur utilisation médicale
EP3331544A4 (fr) Identification de glycopeptides associés à mhc de catégorie i comme cibles d'immunothérapie de cancer
EP3313427A4 (fr) Peptides thérapeutiques et leurs procédés d'utilisation
EP3169354A4 (fr) Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
EP3336186A4 (fr) Peptide dérivé du depdc1 et vaccin le contenant
AU2015300256B2 (en) KOC1-Derived peptide and vaccine including same
EP3189852A4 (fr) Composition pharmaceutique vaccinale renfermant un bisphosphonate, destinée à induire l'immunité humorale
EP3162378A4 (fr) Système de rhinovaccination pour vaccin contre la grippe
EP3324990A4 (fr) Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie
EP3222289A4 (fr) Vaccin de combinaison adn-peptide

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20170217

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BRIAN J. CZERNIECKI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CZERNIECKI, BRIAN J.

Inventor name: KOSKI, GARY K.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190301

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 2/00 20060101ALI20190225BHEP

Ipc: A61K 38/16 20060101ALI20190225BHEP

Ipc: G01N 33/574 20060101ALI20190225BHEP

Ipc: G01N 33/569 20060101ALI20190225BHEP

Ipc: A61K 38/00 20060101ALI20190225BHEP

Ipc: A61K 39/00 20060101AFI20190225BHEP

Ipc: C07K 16/28 20060101ALI20190225BHEP

Ipc: A61P 35/00 20060101ALI20190225BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20211103